Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine

标题
Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 33, Issue 5, Pages 524-524
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2015-01-13
DOI
10.1200/jco.2014.57.5621

向作者/读者发起求助以获取更多资源

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now